Singularity Pharma

Profile

Singularity Pharma is a drug discovery company developing novel drugs to treat CNS disorders with unmet needs. By applying medicinal chemistry and phenotypic screening to overlooked drugs we aim to develop new compounds with superior therapeutic potential that can be advanced along a regulatory pathway to better meet the needs of patients.

Singularity’s lead program’s first in-class NCEs are inspired by alkaloids of known drugs whose unregulated usage patterns suggest robust analgesia and leverage a unique mechanism of action for pain therapeutics. Singularity is in lead optimization with a novel chemical scaffold protected by a broad portfolio of composition of matter pending patents covering this and related novel scaffolds. This scaffold shows in-vivo pharmacology differentiating Singularity’s compounds from other pain programs with initial indications targeting post-operative pain in fragile and respiratory-compromised patient populations.

Website

singularity-pharma.com

Contact


Event details

Date: October 7 - 9, 2026

Event contact

Stephen Ip
Senior International Market Consultant
Japan and Korea

Participants

13 in total